1-7 of 7
Yuan Ji, PhD
Close
Sort by
Journal Articles

Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma,

Anas Younes, MD, Amanda Copeland, MSN, Michelle A. Fanale, MD, Luis Fayad, MD, Jorge E Romaguera, MD, Larry W Kwak, MD, PhD, Sattva S. Neelapu, MD, Fredrick Hagemeister, MD, Barbara Pro, MD, Silvana de Castro Faria, MD, Yuan Ji, PhD, Donald Berry, Daniela Buglio, MD, PhD, L. Jeffrey Medeiros, MD
Journal: Blood
Blood (2011) 118 (21): 3718.
https://doi.org/10.1182/blood.V118.21.3718.3718
Published: 2011
Journal Articles

Combined Inhibition of Janus and Aurora Kinases by the Novel Small Molecule Inhibitor AZD1480 Induces Cell Death and Downregulates PD-L1 and PD-L2 Expression In Hodgkin Lymphoma

Enrico Derenzini, MD, Daniela Buglio, MD, PhD, Hiroshi Katayama, PhD, Yuan Ji, PhD, Subrata Sen, PhD, Anas Younes, MD
Journal: Blood
Blood (2010) 116 (21): 2848.
https://doi.org/10.1182/blood.V116.21.2848.2848
Published: 2010
Journal Articles

Inhibition of Tak-1 by AZ-Tak1 Impairs NF-κB Activation, Downregulates XIAP and Activates Caspase-9 Inducing Apoptosis In Mantle Cell lymphoma

Daniela Buglio, MD, PhD, Sangeetha Palakurti, PhD, Francisco Vega, PhD, Sattva S. Neelapu, Donald Berry, PhD, Yuan Ji, PhD, Kate Byth, PhD, Anas Younes, MD
Journal: Blood
Blood (2010) 116 (21): 2852.
https://doi.org/10.1182/blood.V116.21.2852.2852
Published: 2010
Journal Articles

Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma

Anas Younes, MD, Amanda Copeland, MSN, Michelle A. Fanale, MD, Fredrick Hagemeister, MD, Luis Fayad, MD, Barbara Pro, MD, Silvana C. Faria, MD, PhD, Yuan Ji, PhD, L. Jeffrey Medeiros, MD, Donald A Berry, PhD, Daniela Buglio, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3964.
https://doi.org/10.1182/blood.V116.21.3964.3964
Published: 2010
Journal Articles

Safety and Efficacy of Bortezomib Plus ICE (BICE) for the Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma.

Michelle A. Fanale, MD, Luis Fayad, MD, Barbara Pro, MD, Felipe Samaniego, MD, Gracy Zachariah, RN, Cesar A. Nunez, MD, Yuan Ji, PhD, Anas Younes, MD
Journal: Blood
Blood (2007) 110 (11): 4506.
https://doi.org/10.1182/blood.V110.11.4506.4506
Published: 2007
Journal Articles

High Incidence of Venous Thromboembolism in Patients with Lymphoma Receiving Chemotherapy: Assessment of Risk Factors.

Shyam Teegala, MD, Xiao Zhou, MD, PhD, Auris Huen, PHARMD, Yuan Ji, PhD, Luis Fayad, M.D., Jorge Enrique Romaguera, M.D., F.B. Hagemeister, M.D., Saroj Vadhan-Raj, M.D.
Journal: Blood
Blood (2006) 108 (11): 4103.
https://doi.org/10.1182/blood.V108.11.4103.4103
Published: 2006
Journal Articles

Incidence and Risk Factors for Severe Thrombocytopenia in Lymphoma Patients Receiving Chemotherapy.

Auris Huen, PharmD, Xiao Zhou, MD, PhD, Shyam Teegala, M.D., Yuan Ji, PhD, Luis Fayad, M.D., Jorge Enrique Romaguera, M.D., F.B. Hagemeister, M.D., Saroj Vadhan-Raj, M.D.
Journal: Blood
Blood (2006) 108 (11): 3994.
https://doi.org/10.1182/blood.V108.11.3994.3994
Published: 2006